‹ Back to CONCORDBIO.NS

CONCORDBIO.NS Profit & Loss

Concord Biotech Ltd.

Profit & Loss Balance Sheet Cash Flow

Profit & Loss · 3 years on file (FY2023-24 to FY2025-26) · fetched 2026-08-23 21:43
Line item FY2023-24 FY2024-25 FY2025-26 Source (XBRL element)
Revenue from Operations ₹10.17 Bn ₹12.00 Bn ₹10.55 Bn RevenueFromOperations
Gross Revenue (incl. inter-segment) N/A N/A N/A SegmentRevenueFromOperations
Other Income ₹0.34 Bn ₹0.44 Bn ₹0.52 Bn OtherIncome
Total Income ₹10.51 Bn ₹12.45 Bn ₹11.07 Bn Income
Cost of Materials Consumed ₹1.85 Bn ₹2.64 Bn ₹2.54 Bn CostOfMaterialsConsumed
Purchases of Stock-in-Trade ₹0.57 Bn ₹0.56 Bn ₹0.63 Bn PurchasesOfStockInTrade
Changes in Inventories ₹-0.12 Bn ₹-0.15 Bn ₹-0.71 Bn ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade
Employee Benefit Expense ₹1.23 Bn ₹1.39 Bn ₹1.77 Bn EmployeeBenefitExpense
Finance Costs ₹0.03 Bn ₹0.01 Bn ₹0.00 Bn FinanceCosts
Depreciation and Amortisation ₹0.54 Bn ₹0.54 Bn ₹0.74 Bn DepreciationDepletionAndAmortisationExpense
Other Expenses ₹2.33 Bn ₹2.49 Bn ₹2.65 Bn OtherExpenses
Total Expenses ₹6.42 Bn ₹7.49 Bn ₹7.62 Bn Expenses
Profit Before Exceptional Items and Tax ₹4.09 Bn ₹4.96 Bn ₹3.45 Bn ProfitBeforeExceptionalItemsAndTax
Exceptional Items ₹0.00 Bn ₹0.00 Bn ₹-0.03 Bn ExceptionalItemsBeforeTax
Profit Before Tax ₹4.09 Bn ₹4.96 Bn ₹3.42 Bn ProfitBeforeTax
Tax Expense ₹1.04 Bn ₹1.23 Bn ₹0.85 Bn TaxExpense
Net Profit (incl. minority interest) ₹3.08 Bn ₹3.72 Bn ₹2.59 Bn ProfitLossForPeriod
Net Profit (to shareholders) ₹3.08 Bn ₹3.72 Bn ₹2.61 Bn ProfitOrLossAttributableToOwnersOfParent
Basic EPS ₹29.45 ₹35.52 ₹24.78 BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations
Diluted EPS ₹29.45 ₹35.52 ₹24.78 DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations

Every figure above is the exact value of the named XBRL element from CONCORDBIO.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).